zithromax has been researched along with Pneumonia--Staphylococcal* in 2 studies
2 other study(ies) available for zithromax and Pneumonia--Staphylococcal
| Article | Year |
|---|---|
The Azithromycin Pro-Drug CSY5669 Boosts Bacterial Killing While Attenuating Lung Inflammation Associated with Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus.
Antibiotic resistance is a major problem, with methicillin-resistant Staphylococcus aureus (MRSA) being a prototypical example in surgical and community-acquired infections. S. aureus, like many pathogens, is immune evasive and able to multiply within host immune cells. Consequently, compounds that aid host immunity (e.g., by stimulating the host-mediated killing of pathogens) are appealing alternatives or adjuncts to classical antibiotics. Azithromycin is both an antibacterial and an immunomodulatory drug that accumulates in immune cells. We set out to improve the immunomodulatory properties of azithromycin by coupling the immune activators, nitric oxide and acetate, to its core structure. This new compound, designated CSY5669, enhanced the intracellular killing of MRSA by 45% ± 20% in monocyte-derived macrophages and by 55% ± 15% in peripheral blood leukocytes, compared with untreated controls. CSY5669-treated peripheral blood leukocytes produced fewer proinflammatory cytokines, while in both monocyte-derived macrophages and peripheral blood leukocytes, phagocytosis, ROS production, and degranulation were unaffected. In mice with MRSA pneumonia, CSY5669 treatment reduced inflammation, lung pathology and vascular leakage with doses as low as 0.01 μmol/kg p.o. CSY5669 had diminished direct Topics: Animals; Anti-Bacterial Agents; Azithromycin; Cytokines; Inflammation; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Nitric Oxide; Pneumonia, Staphylococcal; Prodrugs; Reactive Oxygen Species; Staphylococcal Infections; Staphylococcus aureus | 2022 |
Efficacy of Azithromycin in a Mouse Pneumonia Model against Hospital-Acquired Methicillin-Resistant Staphylococcus aureus.
The use of macrolides against pneumonia has been reported to improve survival; however, little is known about their efficacy against methicillin-resistant Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Bacterial Toxins; Daptomycin; Disease Models, Animal; Drug Therapy, Combination; Healthcare-Associated Pneumonia; Hemolysin Proteins; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred BALB C; Pneumonia, Staphylococcal; Vancomycin; Virulence Factors | 2019 |